Khurshid Jalal

Mr. Khurshid Jalal

International Center for Chemical and Biological Sciences, Karachi, Sindh, Pakistan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KJKhurshid Jalal
Khurshid Jalal
KKKanwal Khan
Kanwal Khan
DADiyar Ahmad
Diyar Ahmad
AHAjmal Hayat
Ajmal Hayat
ZBZarrin Basharat
Zarrin Basharat
MSMuhammad Umar Khayam Sahibzada
Muhammad Umar Khayam Sahibzada
Escherichia albertii is characterized as an emerging pathogen, causing enteric infections. It is responsible for high mortality rate, especially in children, elderly, and immunocompromised people. To the best of our knowledge, no vaccine exists to curb this pathogen. Therefore, in current study, we aimed to identify potential vaccine candidates and design chimeric vaccine models against Escherichia albertii from the analysis of publicly available data of 95 strains, using a reverse vaccinology approach. Outer-membrane proteins (n = 4) were identified from core genome as vaccine candidates. Eventually, outer membrane Fimbrial usher (FimD) protein was selected as a promiscuous vaccine candidate and utilized to construct a potential vaccine model. It resulted in three epitopes, leading to the design of twelve vaccine constructs. Amongst these, V6 construct was found to be highly immunogenic, non-toxic, non-allergenic, antigenic, and most stable. This was utilized for molecular docking and simulation studies against six HLA and two TLR complexes. This construct can therefore be used for pan-therapy against different strains of E. albertii and needs to be tested in vitro and in vivo.

7 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KJKhurshid Jalal
Khurshid Jalal
TATareq Abu-Izneid
Tareq Abu-Izneid
KKKanwal Khan
Kanwal Khan
MAMuhammad Abbas
Muhammad Abbas
AHAjmal Hayat
Ajmal Hayat
RUReaz Uddin
Reaz Uddin
Shigellosis is characterized as diarrheal disease that causes a high mortality rate especially in children, elderly and immunocompromised patients. More recently, the World Health Organization advised safe vaccine designing against shigellosis due to the emergence of Shigella dysenteriae resistant strains. Therefore, the aim of this study is to identify novel drug targets as well as the design of the potential vaccine candidates and chimeric vaccine models against Shigella dysenteriae. A computational based Reverse Vaccinology along with subtractive genomics analysis is one of the robust approaches used for the prioritization of drug targets and vaccine candidates through direct screening of genome sequence assemblies. Herein, a successfully designed peptide-based novel highly antigenic chimeric vaccine candidate against Shigella dysenteriae sd197 strain is proposed. The study resulted in six epitopes from outer membrane WP_000188255.1 (Fe (3+) dicitrate transport protein FecA) that ultimately leads to the construction of twelve vaccine models. Moreover, V9 construct was found to be highly immunogenic, non-toxic, non-allergenic, highly antigenic, and most stable in terms of molecular docking and simulation studies against six HLAs and TLRS/MD complex. So far, this protein and multiepitope have never been characterized as vaccine targets against Shigella dysenteriae. The current study proposed that V9 could be a significant vaccine candidate against shigellosis and to ascertain that further experiments may be applied by the scientific community focused on shigellosis.

12 April 2022 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
KJKhurshid Jalal
Khurshid Jalal
KKKanwal Khan
Kanwal Khan
ZBZarrin Basharat
Zarrin Basharat
MAMuhammad Naseer Abbas
Muhammad Naseer Abbas
RUReaz Uddin
Reaz Uddin
Syed Shams ul HassanSyed Shams ul Hassan
Syed Shams ul Hassan

8 February 2022 in Genomics
Verified
Journal Article
Open access
KKKanwal Khan
Kanwal Khan
KJKhurshid Jalal
Khurshid Jalal
RUReaz Uddin
Reaz Uddin
Salmonella typhi is notorious for causing enteric fever which is also known as typhoid fever. It emerged as an extreme drug resistant strain that requires urgent attention to prevent its global spread. Statistically, about 11-17 million typhoid illnesses are reported worldwide annually. The only alternative approach for the control of this illness is proper vaccination. However, available typhoid vaccine has certain limitations such as poor long-term efficacy, and non-recommendation for below 6 years children, which opens the avenues for designing new vaccines to overcome such limitations. Computational-based reverse vaccinology along with subtractive genomics analysis is one of the robust approaches used for the prioritization of vaccine candidates through direct screening of genome sequence assemblies. In the current study, we have successfully designed a peptide-based novel antigen chimeric vaccine candidate against the XDR strain of S. typhi H58. The pipeline revealed four peptides from WP_001176621.1 i.e., peptidoglycan-associated lipoprotein Pal and two peptides from WP_000747548.1 i.e., OmpA family lipoprotein as promising target for the induction of immune response against S. typhi. The six epitopes from both proteins were found as immunogenic, antigenic, virulent, highly conserved, nontoxic, and non-allergenic among whole Salmonella H58 proteome. Furthermore, the binding interaction between a chimeric vaccine and human population alleles was unveiled through structure-based studies. So far, these proteins have never been characterized as vaccine targets against S. typhi. The current study proposed that construct V2 could be a significant vaccine candidate against S. typhi H58. However, to ascertain this, future experimental holistic studies are recommended as follow-up.

1 February 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
ZBZarrin Basharat
Zarrin Basharat
UAUmaima Akhtar
Umaima Akhtar
KKKanwal Khan
Kanwal Khan
GAGhallab Alotaibi
Ghallab Alotaibi
KJKhurshid Jalal
Khurshid Jalal
SHSyed Shah Hassan
Syed Shah Hassan

25 October 2023 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
AAAhad Amer Alsaiari
Ahad Amer Alsaiari
MHMohammed Ageeli Hakami
Mohammed Ageeli Hakami
BABader S. Alotaibi
Bader S. Alotaibi
SASamia S. Alkhalil
Samia S. Alkhalil
AHAli Hazazi
Ali Hazazi
FYFarzana Yasmin
Farzana Yasmin